dalteparin has been researched along with Astrocytoma, Grade IV in 1 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Robins, HI | 1 |
| O'Neill, A | 1 |
| Gilbert, M | 1 |
| Olsen, M | 1 |
| Sapiente, R | 1 |
| Berkey, B | 1 |
| Mehta, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study to Evaluate the Effect of Dalteparin and Radiation Therapy on Survival Compared to the RTOG RPA Database and on Thromboembolic Events in Patients With Newly Diagnosed Glioblastoma Multiforme[NCT00028678] | Phase 2 | 45 participants (Actual) | Interventional | 2002-07-11 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for dalteparin and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Effect of dalteparin and radiation on survival and thromboembolic events in glioblastoma multiforme: a phase II ECOG trial.
Topics: Adult; Aged; Anticoagulants; Brain Neoplasms; Combined Modality Therapy; Dalteparin; Disease-Free Su | 2008 |